초록 ▼

The invention is directed to a herbal medicinal composition for preventing or treating type II diabetes. The composition is comprised of extracts from Pterocarpus marsupium, Morus alba, Orthosiphon aristatus, Opiophogon japonicus, Rosa rugosa, Commelina communis, Trichosanthis kirilowii and Anemarrh

The invention is directed to a herbal medicinal composition for preventing or treating type II diabetes. The composition is comprised of extracts from Pterocarpus marsupium, Morus alba, Orthosiphon aristatus, Opiophogon japonicus, Rosa rugosa, Commelina communis, Trichosanthis kirilowii and Anemarrhena asphodeloides.

대표청구항 ▼

1. A hypoglycemic effective composition comprising extracts from Pterocarpus marsupium, Morus alba, Orthosiphon aristatus, Opiophogon japonicus, Anemarrhena asphodeloides, or Trichosanthis kirilowii, in combination with extracts from Rosa rugosa and/or Commelina communis, and a pharmaceutically acce

1. A hypoglycemic effective composition comprising extracts from Pterocarpus marsupium, Morus alba, Orthosiphon aristatus, Opiophogon japonicus, Anemarrhena asphodeloides, or Trichosanthis kirilowii, in combination with extracts from Rosa rugosa and/or Commelina communis, and a pharmaceutically acceptable carrier thereof, wherein said extracts are present in a ratio of: about 20% by weight of Pterocarpus marsupium, about 15% by weight of Morus alba, about 20% by weight of Orthosiphon aristatus, about 10% by weight of Opiophogon japonicus, about 8% by weight of Rosa rugosa, about 7% by weight of Commelina communis, about 10% by weight of Trichosanthis kirilowii, and about 10% by weight of Anemarrhena asphodeloides. 2. The composition according to claim 1, wherein said carrier is a base of berries or fruit, a base of vegetable soup or bouillon, a soya-milk drink, or a nutritive supplement. 3. The composition according to claim 2, wherein said base of berries or fruit comprises extracts from Rosa canina, Vaccinum myrtillus or Vaccinum vitis-idea. 4. The composition according to claim 2, wherein said base of vegetable soup or bouillon comprises extracts from Urtica diotica leaves, Allium cepa, or Ocimum sanctum. 5. The composition according to claim 1, which further comprises extracts from Arctium lappa root, Eugenia jambolana seeds, Phaseus vulgaris husks, Trigonella foenum graeam seeds, or Vaccinum myrtillus leaves. 6. The composition according to claim 1, which further comprises chromium, manganese, zinc, niacin, vitamin B6 or vitamin B12. 7. The composition according to claim 6, wherein said chromium is present in an amount of about 20 to about 500 micrograms, manganese is present in an amount of about 1 to about 10 milligrams, zinc is present in an amount of about 2 to about 10 milligrams, niacin is present in an amount of about 50 to about 500 milligrams, vitamin B6 is present in an amount of about 1 to about 50 milligrams, or vitamin B12 is present in an amount of about 5 to about 100 micrograms per dose. 8. The composition according to claim 1, which further comprises extracts from Acanthopanax, Schizandra, and optionally Rhodiola. 9. The composition according to claim 5, which further comprises chromium, manganese, zinc, niacin, vitamin B6 or vitamin B12. 10. The composition according to claim 5, which further comprises extracts from Acanthopanax, Schizandra, and optionally Rhodiola. 11. The composition according to claim 6, which further comprises extracts from Acanthopanax, Schizandra, and optionally Rhodiola. 12. The composition according to claim 9, which further comprises extracts from Acanthopanax, Schizandra, and optionally Rhodiola. 13. The composition according to claim 8, wherein the extracts of Acanthopanax senticosus root, Schizandra chinensis fruit and seed, and Rhodiola rosea root are present in a ratio of about 4:2:1. 14. A method of treating type II diabetes comprising administering to a person in need thereof a hypoglycemic effective amount of the composition according to claim 1. 15. A method of reducing blood glucose level in a patient who has blood glucose level of about 200 to about 300 mg/dl at the beginning of treatment, comprising administering to said patient a hypoglycemic effective amount of the composition according to claim 1. 16. A method of increasing insulin secretion from pancreatic β cells, comprising administering an effective amount of the composition according to claim 1 to an individual. 17. A method of inhibiting degradation of complex carbohydrates to monosaccharides, comprising administering the composition according to claim 1 to an individual.